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The availability of blood-based markers
to predict response of a solid tumor to
treatment, estimate patient prognosis and
diagnose relapse well before clinical
symptoms arise, is a long-standing hope in
clinical oncology. Ideally, assays designed
to provide such information should be
inexpensive (at least in the foreseeable
future), simple, and, of course, predictive
of the clinical evolution of the disease.
While early research focused on circulat-
ing glycosylated tumor-derived protein
biomarkers, the focus is now rapidly
shifting to new opportunities, such as
circulating tumor cells, extracellular
vesicles, micro-RNAs and cancer-derived
cell-free DNA a.k.a. circulating tumor-
derived DNA (ctDNA).
See also: E Olsson et al (August 2015)
I n this issue of EMBO Molecular Medicine,Olsson et al (2015) provide excitingevidence for the value of ctDNA measure-
ments in early-stage breast cancer. Based on
their results, elevated plasma ctDNA levels
preceded clinical detection of relapse in 86%
of the patients with an average lead-time of
11 months. Admittedly, this is a small retro-
spective study of 20 patients that needs to
be validated as well as expanded and
extended, but it is nevertheless a promising
proof-of-concept for prospective transla-
tional and clinical studies. The study also
points to a number of methodological
aspects that may need to be considered by
investigators studying ctDNA in any type of
cancer.
The authors studied 20 patients with
primary breast cancer who underwent
surgery and adjuvant chemo- or radiation
therapy. The primary tumors were
sequenced to identify patient-specific genetic
alterations, followed by the design of
specific digital droplet PCR (dd-PCR) assays
to detect these alterations in plasma
samples. The main goal was to investigate
whether the patient-specific plasma ctDNA
assay could detect disease relapse and occult
metastatic disease before clinical evidence of
the recurrence. Rising ctDNA levels
predicted clinical evidence of metastasis
with an average lead-time of 11 months.
The assay had a 93% sensitivity and 100%
specificity. Thus, a positive plasma ctDNA
test was always eventually followed by clini-
cal detection of metastasis. Additionally,
high ctDNA levels before surgery predicted
poor disease-free outcome and overall
survival. This suggests that ctDNA levels
could in the future define patients who need
additional adjuvant therapies after primary
surgery. Although this study was not
powered to fully evaluate the predictive and
prognostic value of the plasma ctDNA assay,
it serves as a strong stimulus for additional
and larger clinical follow-up studies.
Compared to previous studies, the Olsson
et al (2015) study provides a very optimistic
picture about the sensitivity of ctDNA assays
in primary breast cancer. Many previous
studies had focused on metastatic disease,
where the ctDNA concentrations are much
higher (Murtaza et al, 2013). In a large
study across different cancer types, Bette-
gowda et al (2014) found detectable levels
of plasma ctDNA in 49–78% of patients with
localized tumors from breast, colon,
pancreas, and gastroesophageal cancers as
well as in 86–100% of patients with meta-
static tumors. Overall, in previous studies,
ctDNA has already been reported to be
useful for quantitation of tumor burden in
response to surgery, treatments or as a
measure of overall survival in a number of
malignances, such as colorectal (Leary et al,
2010), breast (Dawson et al, 2013), ovarian
and lung cancer (Murtaza et al, 2013).
The Olsson et al (2015) study also
features several technical and methodologi-
cal improvements that may contribute to
optimal sensitivity and specificity. Firstly,
blood was sampled serially: prior to surgery
and at approximately 3–8, 12, 24, and
36 months after the primary operation. This
longitudinal sampling is a significant advan-
tage as it enables systematic comparison of
plasma ctDNA levels with subsequent clini-
cal progression of the disease. Secondly, the
choice of the methods applied for plasma
DNA isolation may be critical. In this study,
the authors used a commercial kit, which
although not previously validated for this
purpose, appears promising based on the
results obtained. Thirdly, 0.5 ml plasma
samples were used to isolate circulating
DNA, which is a smaller volume compared
to many previous studies and suggests
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outstanding sensitivity of the assay.
Fourthly, the authors selected about 10
tumor-specific rearrangements from the
WGS data for each patient and validated 4–6
of these as dd-PCR assays from the
diagnostic plasma sample. The increasing
evidence pointing to tumor clonal heteroge-
neity as well as evolution during tumor
progression raises significant concerns about
how well the genomic makeup of the
primary tumor reflects all the subclones in
the eventual metastatic disease. As a conse-
quence, the authors selected their dd-PCR
assays to target genomic rearrangements
with varying allele frequencies. Thus, if one
such subclone was selected for, and became
the dominating clone after relapse or in the
metastases, this would be more likely to be
detectable in the plasma ctDNA assay with
this strategy.
Assuming that the results of this study
will be validated in larger clinical studies
with standardized, diagnostic-grade assays,
is the plasma ctDNA assay otherwise appli-
cable in clinical routine? Many additional
considerations are required to answer this
question. Will the prognostic and/or predic-
tive value of ctDNA assays, such as for the
detection of minimal residual disease, actu-
ally lead to clinical improvements in therapy
or patient survival? This will be critical to
investigate and will obviously be also depen-
dent on the available therapeutic options to
treat such sub-clinical disease. Will the
whole-genome sequencing of the primary
tumor (and matching germline DNA),
followed by tailored dd-PCR assays, become
practically and economically feasible and
will the results be obtainable in a timely
fashion to help patients prospectively in
clinical practice? The answer to all these
questions in the near future will probably
be “yes”, given the significant decrease in
genome sequencing costs and opportunities
for laboratory automation. Indeed, even
unbiased whole-genome sequencing of
plasma ctDNA appears feasible in the near
future (Leary et al, 2012), given the progress
of sequencing technology at low template
levels, such as single cells (Wang et al,
2014). The advantage of unbiased plasma
ctDNA sequencing would be to obtain an
overview of the multiple subclones that may
co-exist in a patient with advanced disease,
although it will obviously not achieve the
depth of coverage and cancer specificity of
carefully designed targeted PCR assays. We
also need to better understand how ctDNA
levels correlate with short-term therapeutic
effects (e.g., therapeutic effects associated
with cell killing and increased release of
ctDNA in the plasma) and with long-term
impact due to the remaining tumor mass in
the body. A sharper picture of the biology
and kinetics of ctDNA release and turnover
should expand the utility of circulating
nucleic acids as tumor markers.
In conclusion, plasma ctDNA assays
represent a promising, highly customized
diagnostic technology that may help us tran-
sition toward truly personalized oncology,
whereby it will become possible to monitor
and consequently optimize the therapeutic
impact of any surgical, radiotherapy, or drug
treatment in real-time.
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